Engineering stability into Escherichia coli secreted Fabs leads to increased functional expression.

No abstract is available for this paper.

• Publication year

  2006

• Venue

  Protein engineering, design & selection : PEDS

• Publication date

  2006-07-01

• Fields of study

  Biology, Medicine, Engineering

• Identifiers
  DOI 10.1093/PROTEIN/GZL016PMID 16672248
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Domain interactions in the Fab fragment: a comparative evaluation of the single-chain Fv and Fab format engineered with variable domains of different stability.

  2005cited by this paper
• Phage-displayed antibody libraries of synthetic heavy chain complementarity determining regions.

  2004cited by this paper
• Aggregation-resistant domain antibodies selected on phage by heat denaturation

  2004cited by this paper
• Optimization of the antibody C(H)3 domain by residue frequency analysis of IgG sequences.

  2004cited by this paper
• Stability improvement of antibodies for extracellular and intracellular applications: CDR grafting to stable frameworks and structure-based framework engineering.

  2004cited by this paper
• Structural and Thermodynamic Characterization of Pal, a Phage Natural Chimeric Lysin Active against Pneumococci*

  2004cited by this paper
• Gene site saturation mutagenesis: a comprehensive mutagenesis approach.

  2004cited by this paper
• Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab

  2003cited by this paper
• Biophysical properties of human antibody variable domains.

  2003cited by this paper
• Structure-based improvement of the biophysical properties of immunoglobulin VH domains with a generalizable approach.

  2003cited by this paper
• The PyMOL Molecular Graphics System

  2002cited by this paper
• Knowledge-based potential functions in protein design.

  2002cited by this paper
• Yet another numbering scheme for immunoglobulin variable domains: an automatic modeling and analysis tool.

  2001cited by this paper
• Tailoring in vitro evolution for protein affinity or stability.

  2001cited by this paper
• Stability engineering of antibody single-chain Fv fragments.

  2001cited by this paper
• The unfolding/denaturation of immunogammaglobulin of isotype 2b and its F(ab) and F(c) fragments.

  2000cited by this paper
• Fully synthetic human combinatorial antibody libraries (HuCAL) based on modular consensus frameworks and CDRs randomized with trinucleotides.

  2000cited by this paper
• FEBS Lett

  2000cited by this paper
• The identification of conserved interactions within the SH3 domain by alignment of sequences and structures

  2000cited by this paper
• The hierarchy of mutations influencing the folding of antibody domains in Escherichia coli.

  1999cited by this paper
• High thermal stability is essential for tumor targeting of antibody fragments: engineering of a humanized anti-epithelial glycoprotein-2 (epithelial cell adhesion molecule) single-chain Fv fragment.

  1999cited by this paper
• A Large Non-immunized Human Fab Fragment Phage Library That Permits Rapid Isolation and Kinetic Analysis of High Affinity Antibodies*

  1999cited by this paper
• A single backmutation in the human kIV framework of a previously unsuccessfully humanized antibody restores the binding activity and increases the secretion in cos cells.

  1999cited by this paper
• Design of highly stable functional GroEL minichaperones

  1999cited by this paper
• Exploiting antibody-based technologies to manage environmental pollution.

  1999cited by this paper
• Intrabody construction and expression. I. The critical role of VL domain stability.

  1999cited by this paper
• Stabilization of antibody fragments in adverse environments

  1998cited by this paper
• Efficient construction of a large nonimmune phage antibody library: the production of high-affinity human single-chain antibodies to protein antigens.

  1998cited by this paper
• Antibody engineering: comparison of bacterial, yeast, insect and mammalian expression systems.

  1998cited by this paper
• Semirational design of active tumor suppressor p53 DNA binding domain with enhanced stability.

  1998cited by this paper
• Contribution of domain interface residues to the stability of antibody CH3 domain homodimers.

  1998cited by this paper
• Structural determinants in the sequences of immunoglobulin variable domain.

  1998cited by this paper
• Antibody scFv fragments without disulfide bonds made by molecular evolution.

  1998cited by this paper
• Mutual stabilization of VL and VH in single-chain antibody fragments, investigated with mutants engineered for stability.

  1998cited by this paper
• Disrupting the hydrophobic patches at the antibody variable/constant domain interface: improved in vivo folding and physical characterization of an engineered scFv fragment.

  1997cited by this paper
• Engineering antibodies for imaging and therapy.

  1997cited by this paper
• Human Antibodies with Sub-nanomolar Affinities Isolated from a Large Non-immunized Phage Display Library

  1996cited by this paper
• Selection and evolution of high-affinity human anti-viral antibodies.

  1996cited by this paper
• Functional antibody single-chain fragments from the cytoplasm of Escherichia coli: influence of thioredoxin reductase (TrxB).

  1995cited by this paper
• Phage display of disulfide-stabilized Fv fragments.

  1995cited by this paper
• Comparative thermodynamic analyses of the Fv, Fab* and Fab fragments of anti-dansyl mouse monoclonal antibody.

  1995cited by this paper
• Denaturant m values and heat capacity changes: Relation to changes in accessible surface areas of protein unfolding

  1995cited by this paper
• Engineered turns of a recombinant antibody improve its in vivo folding.

  1995cited by this paper
• Sequence statistics reliably predict stabilizing mutations in a protein domain.

  1994cited by this paper
• A map of the human immunoglobulin VH locus completed by analysis of the telomeric region of chromosome 14q

  1994cited by this paper
• Isolation of high affinity human antibodies directly from large synthetic repertoires.

  1994cited by this paper
• Antigen binding thermodynamics and antiproliferative effects of chimeric and humanized anti-p185HER2 antibody Fab fragments.

  1992cited by this paper
• Therapeutic Human Antibodies Derived from PCR Amplification of B‐Cell Variable Regions

  1992cited by this paper
• Information‐theoretical entropy as a measure of sequence variability

  1991cited by this paper
• Thermodynamics of the binding of L-arabinose and of D-galactose to the L-arabinose-binding protein of Escherichia coli.

  1983cited by this paper
• Noncovalent association of heavy and light chains of human immunoglobulins. III. Specific interactions between VH and VL.

  1982cited by this paper
• Tetanus toxin

  1979cited by this paper
• Equilibrium and kinetics of the denaturation of a homogeneous human immunoglobulin light chain.

  1973cited by this paper

• Single-residue engineering of lambda (λ) antibody light chains reduces conformational flexibility and enhances thermal stability

  2025cites this paper
• Design of an alternate antibody fragment format that can be produced in the cytoplasm of Escherichia coli

  2023cites this paper
• Engineered Human Antibody with Improved Endothelin Receptor Type A Binding Affinity, Developability, and Serum Persistence Exhibits Excellent Antitumor Potency.

  2022cites this paper
• DutaFabs are engineered therapeutic Fab fragments that can bind two targets simultaneously

  2021cites this paper
• Thermal and Chemical Unfolding of a Monoclonal IgG1 Antibody: Application of the Multistate Zimm-Bragg Theory

  2020cites this paper
• Differential scanning calorimetry in the biopharmaceutical sciences

  2020cites this paper
• Unveiling the secrets of DNA : Improved expression and phage display efficiency of synthetic recombinant binding proteins in E. coli through modulation of codon usage

  2020cites this paper
• Solubility, Stability, and Avidity of Recombinant Antibody Fragments Expressed in Microorganisms

  2020cites this paper
• Expression vector cassette engineering for recombinant therapeutic production in mammalian cell systems

  2020cites this paper
• Improvement in the thermal stability of Mucor prainii-derived FAD-dependent glucose dehydrogenase via protein chimerization.

  2020cites this paper
• Thermal and Chemical Unfolding of a recombinant monoclonal IgG1 antibody: Application of the Multi-State Zimm-Bragg Theory

  2019cites this paper
• Design and Production of Bispecific Antibodies

  2019cites this paper
• Ubiquitin Engineering: Understanding Ubiquitin Recognition and Generating Affinity Reagents

  2017cites this paper
• Optimizing antibody expression: The nuts and bolts.

  2017cites this paper
• Engineering antibody therapeutics and cell culture models for neurodegenerative diseases

  2016cites this paper
• Comparing domain interactions within antibody Fabs with kappa and lambda light chains

  2016cites this paper
• Increased Fab thermoresistance via VH-targeted directed evolution.

  2015influential citation
• Advanced analyses of kinetic stabilities of iggs modified by mutations and glycosylation

  2015cites this paper
• Optimizing antibody expression by using the naturally occurring framework diversity in a live bacterial antibody display system

  2015cites this paper
• Increasing stability of antibody via antibody engineering: Stability engineering on an anti‐hVEGF

  2014cites this paper
• Formulation and Characterisation of Antibody-Conjugated Soy Protein Nanoparticles—Implications for Neutralisation of Snake Venom with Improved Efficiency

  2014cites this paper
• Using DSC to study antibody Fab region stability for improved biotherapeutic development

  2014influential citation
• Highly covarying residues have a functional role in antibody constant domains

  2013cites this paper
• Secretion from bacterial versus mammalian cells yields a recombinant scFv with variable folding properties.

  2012cites this paper
• Engineering an Improved IgG4 Molecule with Reduced Disulfide Bond Heterogeneity and Increased Fab Domain Thermal Stability

  2012cites this paper
• Transfer of engineered biophysical properties between different antibody formats and expression systems.

  2012cites this paper
• Engineering aggregation-resistant antibodies.

  2012cites this paper
• Relative stabilities of IgG1 and IgG4 Fab domains: Influence of the light–heavy interchain disulfide bond architecture

  2012cites this paper
• Antibody expression and production

  2011cites this paper
• Structural and energetic hot-spots for the interaction between a ladder-like polycyclic ether and the anti-ciguatoxin antibody 10C9Fab.

  2011cites this paper
• Enhancing the thermal stability of a single-chain Fv fragment by in vivo global fluorination of the proline residues.

  2011cites this paper
• Production of Antibody Fab Fragments in Escherichia coli

  2011cites this paper
• Microbial hosts can be used to express a range of antibodies and antibody fragments. The different types of fragments need to be understood, including the features that are critical to successful expression, along with the potential advantages and disadvantages.

  2011cites this paper
• Engineering Proteins from Sequence Statistics: Identifying and Understanding the Roles of Conservation and Correlation in Triosephosphate Isomerase

  2011influential citation
• Expression of HCV glycoprotein E1 and its evaluation for vaccine development

  2011cites this paper
• Optimierte konstante Domänen für die effektive Expression von Fab-Fragmenten in E. coli

  2010cites this paper
• Stable IgG-like Bispecific Antibodies Directed toward the Type I Insulin-like Growth Factor Receptor Demonstrate Enhanced Ligand Blockade and Anti-tumor Activity

  2010cites this paper
• Stability engineering of scFvs for the development of bispecific and multivalent antibodies.

  2010cites this paper
• Antibody Engineering for Biosensor Applications

  2010cites this paper
• A system for repertoire cloning and phage display of murine and leporid antibody fragments.

  2010cites this paper
• Rationale and development of multispecific antibody drugs

  2010cites this paper
• Generic Approach for the Generation of Stable Humanized Single-chain Fv Fragments from Rabbit Monoclonal Antibodies

  2010cites this paper
• Conserved amino acid networks involved in antibody variable domain interactions

  2009cites this paper
• Rapid screening platform for stabilization of scFvs in Escherichia coli.

  2009cites this paper
• Engineering of stable bispecific antibodies targeting IL-17A and IL-23.

  2009cites this paper
• Proteins: Thermal Unfolding

  2009cites this paper
• How Protein Recognizes Ladder-like Polycyclic Ethers

  2008cites this paper
• Engineering Hyperthermostability into a GH11 Xylanase Is Mediated by Subtle Changes to Protein Structure*

  2008cites this paper
• Thermostable llama single domain antibodies for detection of botulinum A neurotoxin complex.

  2008cites this paper
• Biotherapeutics.

  2008cites this paper
• Antibody therapeutics, antibody engineering, and the merits of protein stability.

  2008cites this paper
• APEx 2-hybrid, a quantitative protein–protein interaction assay for antibody discovery and engineering

  2007cites this paper
• Framework shuffling of antibodies to reduce immunogenicity and manipulate functional and biophysical properties.

  2007cites this paper
• A broad range of Fab stabilities within a host of therapeutic IgGs.

  2007cites this paper
• Microcalorimetry: a response to challenges in modern biotechnology

  2007cites this paper
• Highly Covarying Residues Have a Functional Role in Antibody Constant Domains

  year unknowncites this paper